Ge healthcare announces first patient dosed in phase iii clinical trial for new dopamine transporter imaging radiopharmaceutical

Marlborough, mass.--(business wire)--ge healthcare has today announced the first patient dosed in the phase iii clinical trial for a positron emission tomography (pet) radiopharmaceutical imaging agent which aims to assist in the evaluation of adult patients with suspected parkinsonian syndromes, support research and improve patient care. already a global leader with datscan ([123i]-ioflupane), used in single-photon emission computed tomography (spect) imaging across more than 40 countries worl
GE Ratings Summary
GE Quant Ranking